The Missouri case was detected through routine flu season surveillance, said the CDC, and is also the first time that an H5 ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa ...

The agreement ties in with Lilly's strategy of making genetic medicines targeting DNA and RNA a key pillar of its R&D, ...

The headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically ...

AstraZeneca has confirmed that some of its current and former employees have been taken into custody in China as part of an ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), ...

The CEO's departure comes after Lykos co-founder and longtime psychedelic medicines advocate Rick Doblin stood down from the ...

The company recently claimed FDA approval for the first description DTx for major depressive disorder (MDD) – ...

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies ...

Pay a tax of up to 1,900% (not 95%) on the total sales revenue of the medicine selected for price setting. News coverage ...

Emergent BioSolutions, which is one of only three companies with a vaccine for mpox, has agreed to donate 50,000 doses of ...

Fabhalta (iptacopan) was approved by UK drugs regulator the MHRA last month, becoming an option for an estimated 220 out of ...